WO2002082075A3 - Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien - Google Patents

Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien Download PDF

Info

Publication number
WO2002082075A3
WO2002082075A3 PCT/DE2002/001376 DE0201376W WO02082075A3 WO 2002082075 A3 WO2002082075 A3 WO 2002082075A3 DE 0201376 W DE0201376 W DE 0201376W WO 02082075 A3 WO02082075 A3 WO 02082075A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
disease
alzheimer
detection reagents
corresponding peptides
Prior art date
Application number
PCT/DE2002/001376
Other languages
English (en)
French (fr)
Other versions
WO2002082075A9 (de
WO2002082075A2 (de
Inventor
Norbert Lamping
Hans-Dieter Zucht
Gabriele Heine
Michael Juergens
Ruediger Hess
Hartmut Selle
Markus Kellmann
Original Assignee
Biovision Ag
Norbert Lamping
Hans-Dieter Zucht
Gabriele Heine
Michael Juergens
Ruediger Hess
Hartmut Selle
Markus Kellmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovision Ag, Norbert Lamping, Hans-Dieter Zucht, Gabriele Heine, Michael Juergens, Ruediger Hess, Hartmut Selle, Markus Kellmann filed Critical Biovision Ag
Priority to EP02742678A priority Critical patent/EP1373905A2/de
Priority to JP2002579794A priority patent/JP2004531250A/ja
Priority to DE10291524T priority patent/DE10291524D2/de
Priority to CA002446886A priority patent/CA2446886A1/en
Priority to AU2002338348A priority patent/AU2002338348A1/en
Publication of WO2002082075A2 publication Critical patent/WO2002082075A2/de
Publication of WO2002082075A9 publication Critical patent/WO2002082075A9/de
Publication of WO2002082075A3 publication Critical patent/WO2002082075A3/de
Priority to US10/680,087 priority patent/US20040142388A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Die vorliegende Erfindung betrifft definierte Peptide und deren quantitative Bestimmung in biologischen Proben von Patienten, die an Morbus Alzheimer erkrankt sind, relativ zu deren Konzentration in einer Kontrollgruppe. Ausserdem betrifft die Erfindung die Verwendung der Peptide zu therapeutischen Zwecken. Die erfindungsgemässen Peptide entstammen aus einem Proteinvorläufer mit dem korrespondierenden Gen und sind in spezifischer Art und Weise prozessiert und postranslational modifiziert. Änderungen der Konzentrationen dieser Peptide zeigen eine Morbus Alzheimer Erkrankung an. Dabei ist die Richtung der Konzentrationsänderung für jedes dieser Peptide spezifisch. Der Nachweis von Morbus Alzheimer erfolgt durch eine Identifizierung der Peptide einzeln oder in Kombinationen. Die Erfindung findet darüber hinaus Verwendung zur Verlaufskontrolle von Morbus Alzheimer, zur Prognose und zur Entwicklung von Therapeutika gegen Morbus Alzheimer.
PCT/DE2002/001376 2001-04-06 2002-04-08 Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien WO2002082075A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP02742678A EP1373905A2 (de) 2001-04-06 2002-04-08 Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
JP2002579794A JP2004531250A (ja) 2001-04-06 2002-04-08 慢性痴呆疾患の検出方法、関連ペプチドおよび検出試薬
DE10291524T DE10291524D2 (de) 2001-04-06 2002-04-08 Verfahren zum Nachweis chronisch-demenzieller Erkrankungen, zugehörige Peptide und Nachweisreagenzien
CA002446886A CA2446886A1 (en) 2001-04-06 2002-04-08 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
AU2002338348A AU2002338348A1 (en) 2001-04-06 2002-04-08 Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents
US10/680,087 US20040142388A1 (en) 2001-04-06 2003-10-06 Method for detecting chronic dementia diseases, and corresponding VGF peptides and detection reagents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10117431 2001-04-06
DE10117431.4 2001-04-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/680,087 Continuation-In-Part US20040142388A1 (en) 2001-04-06 2003-10-06 Method for detecting chronic dementia diseases, and corresponding VGF peptides and detection reagents

Publications (3)

Publication Number Publication Date
WO2002082075A2 WO2002082075A2 (de) 2002-10-17
WO2002082075A9 WO2002082075A9 (de) 2002-12-19
WO2002082075A3 true WO2002082075A3 (de) 2003-08-21

Family

ID=7680795

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2002/001376 WO2002082075A2 (de) 2001-04-06 2002-04-08 Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien

Country Status (7)

Country Link
US (1) US20040142388A1 (de)
EP (1) EP1373905A2 (de)
JP (1) JP2004531250A (de)
AU (1) AU2002338348A1 (de)
CA (1) CA2446886A1 (de)
DE (1) DE10291524D2 (de)
WO (1) WO2002082075A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1535076B1 (de) * 2002-08-23 2008-08-06 Bayer HealthCare AG Polypeptid-biomarker zur diagnose von morbus alzheimer
EP1394549A1 (de) 2002-08-23 2004-03-03 Bayer HealthCare AG Biomarker zur Diagnose von Alzheimer Erkrankung
WO2004082455A2 (en) * 2003-03-18 2004-09-30 Biovision Ag Method for detecting alzheimer’s disease and corresponding peptides and detection reagents
WO2004097420A1 (de) * 2003-04-25 2004-11-11 Biovision Ag Verfahren zum nachweis einer neurologischen, demenziellen erkankung, die mit einer verschlechterung des kurz- oder langzeitgedächtnis einhergeht, zugehörige prosaas-peptide und nachweisreagenzien
WO2004110360A2 (en) 2003-05-16 2004-12-23 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
JP2007513337A (ja) * 2003-11-19 2007-05-24 サトリス， インコーポレイテッド アルツハイマー病の診断方法、層化方法およびモニタリング方法
WO2005098446A2 (en) 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
US7749716B2 (en) * 2004-05-18 2010-07-06 Vermilllion, Inc. Methods of detecting a fragment of neurosecretory protein VGF for diagnosing alzheimer's disease
WO2006029840A1 (en) * 2004-09-14 2006-03-23 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
WO2006074787A2 (en) * 2004-12-27 2006-07-20 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
WO2006069739A2 (en) * 2004-12-27 2006-07-06 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
GB0502979D0 (en) 2005-02-14 2005-03-16 Univ Cambridge Tech Biomarkers and uses thereof
JP2008547003A (ja) * 2005-06-16 2008-12-25 バーミリオン， インコーポレイテッド アルツハイマー病についてのバイオマーカーとしての神経分泌タンパク質ｖｇｆのフラグメント
WO2007013586A1 (ja) * 2005-07-29 2007-02-01 Kyowa Hakko Kogyo Co., Ltd. 新規ペプチド
CA2640748C (en) * 2006-02-28 2010-04-20 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
GB0616230D0 (en) 2006-08-16 2006-09-27 Univ Cambridge Tech Biomarkers and uses thereof
EP2123751A4 (de) * 2007-01-25 2010-06-02 Kyowa Hakko Kirin Co Ltd Neues peptid
JP5470050B2 (ja) 2007-02-08 2014-04-16 フェノメノーム ディスカバリーズ インク アルツハイマー型老年認知症の治療方法
JP5483141B2 (ja) * 2008-04-23 2014-05-07 学校法人日本医科大学 脳症由来痙攣と発熱由来熱性痙攣の鑑別方法
WO2010136455A1 (en) * 2009-05-25 2010-12-02 Metabolic Renal Disease, S.L. Methods and reagents for the quantitative determination of metabolites in biological samples
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2013150680A1 (ja) * 2012-04-06 2013-10-10 独立行政法人産業技術総合研究所 プロテインタグ、タグ化タンパク質及びタンパク質精製方法
CN103630623A (zh) * 2013-10-28 2014-03-12 山东东阿阿胶股份有限公司 一种龟甲胶及其制品的检测物及其检测方法
CN103630635B (zh) * 2013-10-30 2015-06-24 山东东阿阿胶股份有限公司 一种胶类中药及其制品中龟源性成分的质谱检测方法
CN116705141B (zh) * 2022-12-15 2024-01-09 西北大学 一种基于cnn-lstm神经网络从核桃酶解产物中筛选阿尔兹海默症预防肽的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
WO2001007074A1 (en) * 1999-07-21 2001-02-01 Amgen, Inc. Vgf selective binding agents and methods of treating vgf-related disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
US20030166555A1 (en) * 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
WO2001007074A1 (en) * 1999-07-21 2001-02-01 Amgen, Inc. Vgf selective binding agents and methods of treating vgf-related disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MIYATAKE Y ET AL: "THE SIGNAL TRANSDUCTION PATHWAY FOR VGF EXPRESSION DUE TO NGF IS DIFFERENT FROM THAT DUE TO BFGF IN PC12H CELL", BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, ACADEMIC PRESS, LONDON, GB, vol. 30, no. 2, June 1993 (1993-06-01), pages 231 - 236, XP000953021, ISSN: 1039-9712 *
PURCELL W M ET AL: "RAT BRAIN MAST CELLS: AN IN VITRO PARADIGM FOR ASSESSING THE TOXIC EFFECTS OF NEUROTROPHIC THERAPEUTICS", NEUROTOXICOLOGY, TOX PRESS, RADFIELD, AR, IN, vol. 17, no. 3/4, 21 September 1996 (1996-09-21), pages 845 - 850, XP008005508, ISSN: 0161-813X *
ROSSI A ET AL: "EXPRESSION IN MURINE AND HUMAN NEUROBLASTOMA CELL LINES OF VGF, A TISSUE SPECIFIC PROTEIN", INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, PERGAMON, OXFORD, GB, vol. 10, no. 6, December 1992 (1992-12-01), pages 527 - 534, XP000953020, ISSN: 0736-5748 *

Also Published As

Publication number Publication date
WO2002082075A9 (de) 2002-12-19
CA2446886A1 (en) 2002-10-17
DE10291524D2 (de) 2004-07-01
WO2002082075A2 (de) 2002-10-17
US20040142388A1 (en) 2004-07-22
EP1373905A2 (de) 2004-01-02
JP2004531250A (ja) 2004-10-14
AU2002338348A1 (en) 2002-10-21

Similar Documents

Publication Publication Date Title
WO2002082075A3 (de) Verfahren zum nachweis chronisch-demenzieller erkrankungen, zugehörige peptide und nachweisreagenzien
Voronova et al. Mutations that disrupt DNA binding and dimer formation in the E47 helix-loop-helix protein map to distinct domains.
ATE348843T1 (de) Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
WO2002089657A3 (en) Diagnostic markers of acute coronary syndromes and methods of use thereof
WO2002054081A3 (en) Proteins, genes and their use for diagnosis and treatment of kidney response
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
AU6279399A (en) Methods and materials for detection and measurement of free radical damage
WO2002090974A3 (de) Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003048775A3 (de) Peptide und verfahren zum nachweis von morbus alzheimer und zur unterscheidung von morbus alzheimer gegenüber anderen demenziellen erkrankungen
SE9500023L (sv) Sätt att detektera cancer
EP0753743A3 (de) Vitamin-D-Bestimmung
WO2001042277A3 (en) Complementary peptide ligands generated from the human genome
DK0750626T3 (da) Stannius-korpuskel-protein, stanniocalcin
WO2004082455A3 (en) Method for detecting alzheimer’s disease and corresponding peptides and detection reagents
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia
WO2002057793A3 (en) Method of detecting prp protein and kits therefor
ATE376595T1 (de) Nachweisverfahren mit biochip
CN108530521A (zh) 重组丙型肝炎抗原的制备及应用
WO2001004349A3 (en) Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease
WO2001069261A3 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
SOLEILHAC et al. Characterization of a soluble form of neutral endopeptidase‐24.11 (EC 3.4. 24.11) in human serum: enhancement of its activity in serum of underground miners exposed to coal dust particles
HUP0101285A2 (hu) Eljárások és készítmények a hepatóma diagnosztizálására
HUP0303491A2 (hu) Magas vérnyomás kvantitatív diagnosztikai elemzése
JP2007167069A (ja) Ｆｓａｐ活性の差異的調節に基づく第ｖｉｉ因子活性化プロテアーゼ（ｆｓａｐ）のマールブルグｉ変異の保因者を同定するための診断方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 3/9-6/9, DRAWINGS, REPLACED BY NEW PAGES 3/10-7/10; PAGES 1/9, 2/9 AND 7/9-9/9 RENUMBERED AS 1/10, 2/10 AND 8/10-10/10

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2446886

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002579794

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10680087

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002742678

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002742678

Country of ref document: EP

REF Corresponds to

Ref document number: 10291524

Country of ref document: DE

Date of ref document: 20040701

Kind code of ref document: P

WWE Wipo information: entry into national phase

Ref document number: 10291524

Country of ref document: DE